American Journal of Cardiovascular Drugs

, Volume 17, Issue 2, pp 109–121 | Cite as

The Rationale for and Clinical Pharmacology of Prasugrel 5 mg

  • Joseph A. JakubowskiEmail author
  • David Erlinge
  • Dimitrios Alexopoulos
  • David S. Small
  • Kenneth J. Winters
  • Paul A. Gurbel
  • Dominick J. Angiolillo
Review Article


Prasugrel is a third-generation thienopyridine platelet P2Y12 adenosine diphosphate (ADP) receptor antagonist administered with aspirin for the treatment of patients with acute coronary syndrome (ACS) with planned percutaneous coronary intervention. Prasugrel is administered periprocedurally at an oral loading dose of 60 mg followed by daily maintenance doses (MDs) of 10 mg for most patients and 5 mg for patients weighing <60 kg or aged ≥75 years. Data from a prasugrel phase III study, TRITON-TIMI 38, suggested that a lower MD might be more suitable for patients weighing <60 kg or aged ≥75 years; subsequent pharmacokinetic and pharmacodynamic studies have indicated that prasugrel 5 mg reduced platelet reactivity in these populations to an extent similar to that of prasugrel 10 mg in heavier or younger patients. Clinical experience with prasugrel 5 mg is limited, and additional studies are needed to verify the clinical efficacy and safety of this dose in these challenging populations.


Percutaneous Coronary Intervention Acute Coronary Syndrome Clopidogrel Maintenance Dose Prasugrel 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Appreciation is expressed to Chris Konkoy, Ph.D. of Eli Lilly and Company and Tamara Ball, MD of inVentiv Health for editorial assistance.

Compliance with Ethical Standards


Dr. Erlinge: Speaker honoraria: Daiichi Sankyo Company, Ltd., Eli Lilly and Company, AstraZeneca; Advisory board: AstraZeneca, Eli Lilly and Company, Merck. Dr. Alexopoulos: Speaker honoraria: AstraZeneca; Advisory Board: AstraZeneca, Boeringer Ingelheim, Bayer. Dr. Gurbel: Consultant: Daiichi Sankyo, Eli Lilly and Company, Bayer, AstraZeneca, Boehringer, Merck and Co., CSL, Janssen, and New Haven Pharmaceuticals; Grants: NIH, Daiichi Sankyo, Merck, New Haven Pharmaceuticals, Haemonetics, Sinnowa, Coramed, and Duke Clinical Research Institute; Patents: in the areas of personalized antiplatelet therapy and interventional cardiology. Dr. Angiolillo: Consulting fee or honorarium: Bayer, Amgen, Pfizer, Sanofi, Daiichi Sankyo, Inc, Eli Lilly and Company, The Medicines Company, AstraZeneca, Merck, Abbott Vascular and PLx Pharma; Review activities: CeloNova, Johnson & Johnson, and St. Jude Medical. Institution; Grants: Glaxo-Smith-Kline, Daiichi Sankyo, Inc, Eli Lilly and Company, The Medicines Company, AstraZeneca, Janssen Pharmaceuticals, Inc., Osprey Medical, Inc., Novartis, CSL Behring, and Gilead. Drs. Jakubowski, Small, and Winters are employees and minor shareholders of Eli Lilly and Company.


This review was funded by Daiichi Sankyo Company, Ltd. and Eli Lilly and Company.


  1. 1.
    EFFIENT (prasugrel). US package insert. Indianapolis, IN: Eli Lilly and Company; 2015. Accessed 4 Nov 2016.
  2. 2.
    Prasugrel (Efient) E.U. Package Insert. Eli Lilly and Company; 2013. Accessed 4 Nov 2016.
  3. 3.
    Daiichi Sankyo Launches Antiplatelet Agent Efient® Tablets 20mg. Daiichi Sankyo and Company, Limited Website 2016. Accessed 4 Nov  2016.
  4. 4.
    Erlinge D, ten Berg JM, Foley D, Angiolillo DJ, Wagner H, Brown PB, et al. Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial. J Am Coll Cardiol. 2012;60(20):2032–949.CrossRefPubMedGoogle Scholar
  5. 5.
    Erlinge D, Gurbel PA,  James S, Lindahl TI, Svensson P, ten Berg JM, et al. Prasugrel 5 mg in the very elderly is non-inferior to prasugrel 10 mg in non-elderly patients: the GENERATIONS trial, a pharmacodynamic (PD) study in stable CAD patients. Eur Heart J. 2012;33(Suppl 675):3915.Google Scholar
  6. 6.
    Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367(14):1297–309.CrossRefPubMedGoogle Scholar
  7. 7.
    Gurbel PA, Erlinge D, Ohman EM, Neely B, Neely M, Goodman SG, et al. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA. 2012;308(17):1785–94.CrossRefPubMedGoogle Scholar
  8. 8.
    Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15.CrossRefPubMedGoogle Scholar
  9. 9.
    Wiviott SD, Antman EM, Gibson CM, Montalescot G, Riesmeyer J, Weerakkody G, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J. 2006;152(4):627–35.CrossRefPubMedGoogle Scholar
  10. 10.
    Riesmeyer JS, Salazar DE, Weerakkody GJ, Ni L, Wrishko RE, Ernest CS, et al. Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy. J Clin Pharmacol. 2012;52(6):789–97.CrossRefPubMedGoogle Scholar
  11. 11.
    Wiviott SD, Desai N, Murphy SA, Musumeci G, Ragosta M, Antman EM, et al. Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. Am J Cardiol. 2011;108(7):905–11.CrossRefPubMedGoogle Scholar
  12. 12.
    Small DS, Li YG, Ernest CS, April JH, Farid NA, Payne CD, et al. Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent. J Clin Pharmacol. 2011;51(3):321–32.CrossRefPubMedGoogle Scholar
  13. 13.
    Jakubowski JA, Payne CD, Weerakkody GJ, Brandt JT, Farid NA, Li YG, et al. Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects. J Cardiovasc Pharmacol. 2007;49(3):167–73.CrossRefPubMedGoogle Scholar
  14. 14.
    Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006;27(10):1166–73.CrossRefPubMedGoogle Scholar
  15. 15.
    Wrishko RE, Ernest CS, Small DS, Li YG, Weerakkody GJ, Riesmeyer JR, et al. Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. J Clin Pharmacol. 2009;49(8):984–98.CrossRefPubMedGoogle Scholar
  16. 16.
    Wagner H, Lood C, Borna C, Gidlof O, Truedsson L, Brown P, et al. Prasugrel 5 mg inhibits platelet P-selectin and GPIIb-IIIa expression in very elderly and non elderly: results from the GENERATIONS trial, a pharmacodynamic study in stable CAD patients. J Thromb Thrombolysis. 2016;42(3):369–75.CrossRefPubMedGoogle Scholar
  17. 17.
    Alexopoulos D, Xanthopoulou I, Plakomyti TE, Theodoropoulos KC, Mavronasiou E, Damelou A, et al. Pharmacodynamic effect of prasugrel 5 mg vs clopidogrel 150 mg in elderly patients with high on-clopidogrel platelet reactivity. Am Heart J. 2013;165(1):73–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Capranzano P, Tamburino C, Capodanno D, Micciche E, D’Urso L, Calvi V, et al. Platelet function profiles in the elderly: results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity. Thromb Haemost. 2011;106(6):1149–57.CrossRefPubMedGoogle Scholar
  19. 19.
    Parodi G, Bellandi B, Comito V, Capodanno D, Valenti R, Marcucci R, et al. Residual platelet reactivity and outcomes with 5 mg prasugrel therapy in elderly patients undergoing percutaneous coronary intervention. Int J Cardiol. 2014;176(3):874–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Cayla G, Cuisset T, Silvain J, Leclercq F, Manzo-Silberman S, Saint-Etienne C, et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet. 2016;388(10055):2015–22.CrossRefPubMedGoogle Scholar
  21. 21.
    Gurbel PA, Bergmeijer TO, Tantry US, ten Berg JM, Angiolillo DJ, James S, et al. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. Thromb Haemost. 2014;112(3):589–97.CrossRefPubMedGoogle Scholar
  22. 22.
    Garabedian T, Alam S. High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance. Cardiovasc Diagn Ther. 2013;3(1):23–37.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Thorn CF, Aklillu E, Klein TE, Altman RB. PharmGKB summary: very important pharmacogene information for CYP1A2. Pharmacogenet Genomics. 2012;22(1):73–7.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Roe MT, Goodman SG, Ohman EM, Stevens SR, Hochman JS, Gottlieb S, et al. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. Circulation. 2013;128(8):823–33.CrossRefPubMedGoogle Scholar
  25. 25.
    Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155–66.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Garratt KN, Weaver WD, Jenkins RG, Pow TK, Mauri L, Kereiakes DJ, et al. Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberte paclitaxel-eluting coronary stent placement. Circulation. 2015;131(1):62–73.CrossRefPubMedGoogle Scholar
  27. 27.
    Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA. 2004;292(6):696–703.CrossRefPubMedGoogle Scholar
  28. 28.
    Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med. 2006;355(10):1006–17.CrossRefPubMedGoogle Scholar
  29. 29.
    Bonaca MP, Braunwald E, Sabatine MS. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;373(13):1274–5.PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Joseph A. Jakubowski
    • 1
    Email author
  • David Erlinge
    • 2
  • Dimitrios Alexopoulos
    • 3
  • David S. Small
    • 1
  • Kenneth J. Winters
    • 1
  • Paul A. Gurbel
    • 4
  • Dominick J. Angiolillo
    • 5
  1. 1.Lilly Research LaboratoriesEli Lilly and CompanyIndianapolisUSA
  2. 2.Department of CardiologyLund UniversityLundSweden
  3. 3.Department of CardiologyAttikon University Hospital, National and Capodistrian University of Athens Medical SchoolAthensGreece
  4. 4.Sinai Center for Thrombosis ResearchBaltimoreUSA
  5. 5.Cardiovascular Research Center at University of Florida College of Medicine-JacksonvilleJacksonvilleUSA

Personalised recommendations